IKK-β
IKK-β (IKBKB) is a catalytic subunit of the IκB kinase (IKK) complex and functions as a central signal integration node that regulates canonical NF-κB signaling, inflammatory responses, cell survival, and immune activation[1]. Mechanistically, activated IKK-β phosphorylates inhibitory IκB proteins, promoting their ubiquitin-dependent degradation and releasing NF-κB transcription factors for nuclear translocation and target gene expression[2]. Through this pathway, IKK-β links extracellular inflammatory stimuli to transcriptional programs that control cytokine production, stress responses, and cellular adaptation[1][3]. In disease contexts, dysregulated IKK-β/NF-κB signaling has been associated with chronic inflammation, cancer, metabolic disorders, cardiovascular disease, and pathogen-driven pathology, making the kinase a widely studied experimental target[1][3]. Compared with the related catalytic isoform IKK-α (CHUK), IKK-β is the predominant kinase mediating canonical NF-κB activation in a NEMO-dependent manner, whereas IKK family members also participate in additional signaling networks beyond classical NF-κB regulation[4]. This functional distinction is important for mechanistic studies aimed at dissecting pathway-specific signaling outputs and inflammatory phenotypes[4]. For experimental applications, pharmacological or genetic inhibition of IKK-β is commonly used to suppress NF-κB activation and evaluate the contribution of inflammatory signaling to disease models, while the expanding spectrum of IKK substrates continues to inform the interpretation of inhibitor-based studies[3][4].
References:
- [1]. Zhang J, et al. IκB kinase β (IKKβ): Structure, transduction mechanism, biological function, and discovery of its inhibitors. Int J Biol Sci. 2023 Aug 6;19(13):4181-4203. [Content Brief]
- [2]. IKK-β gene information from NCBI.
- [3]. Hinz M. The IκB kinase complex in NF-κB regulation and beyond. EMBO Rep. 2014 Jan;15(1):46-61. [Content Brief]
- [4]. Antonia RJ, et al. Expanding the View of IKK: New Substrates and New Biology. Trends Cell Biol. 2021 Mar;31(3):166-178. [Content Brief]
-
IKK-β Related Products (65)
Related Products (65)
-
Antibodies (1)
-
MAP3K1-IN-1
0 ImagesCat. No.: HY-208723CAS No.: 2345648-39-5MAP3K1-IN-1 is an orally active and selective MAP3K1 kinase inhibitor. MAP3K1-IN-1 blocks TNFα-induced phosphorylation of IKKβ and activation of NF-κB. MAP3K1-IN-1 inhibits the growth of cancer cells. MAP3K1-IN-1 induces a decrease in phosphorylation sites of NPM1. MAP3K1-IN-1 can be used in pancreatic cancer-related research.
-
DCLK1-IN-6
0 ImagesCat. No.: HY-178776DCLK1-IN-6 (Compound 12n) is a Doublecortin-like kinase 1 (DCLK1) inhibitor with an IC50 of 58 nM. DCLK1-IN-6 significantly inhibits DCLK1 enzyme activity and its mediated inflammatory pathway. DCLK1-IN-6 has remarkable anti-inflammatory activity and significantly alleviates symptoms in acute lung injury (ALI) and sepsis mouse models. DCLK1-IN-6 can be used for acute inflammation diseases research.
-
2'-Acetylacteoside (Standard)
0 ImagesCat. No.: HY-N0026RCAS No.: 94492-24-7Synonyms: 2'-AA (Standard)2'-Acetylacteoside (Standard) is the analytical standard of 2'-Acetylacteoside (2'-AA) (HY-N0026). This product is intended for research and analytical applications. 2'-Acetylacteoside is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC50 = 17.71 μM, Ki = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease.
-
NF-κB-IN-22
0 ImagesCat. No.: HY-184964CAS No.: 3041997-77-4NF-κB-IN-22 is an inhibitor targeting IKKβ, IκBα and NF-κB p65. NF-κB-IN-22 selectively inhibits the proliferation, migration and invasion of various cancer cells, arrests the cell cycle, and suppresses tumor growth in vivo, while exhibiting low toxicity to normal cells. NF-κB-IN-22 induces DNA damage, ROS production and apoptosis through endoplasmic reticulum stress and mitochondrial apoptotic pathways. NF-κB-IN-22 inhibits the phosphorylation of IKKβ, IκBα and NF-κB p65, blocks the NF-κB signaling pathway, and suppresses the nuclear translocation of NF-κB p65. NF-κB-IN-22 reverses the resistance to cisplatin (HY-17394). NF-κB-IN-22 can be used in research related to lung cancer, gastric cancer and liver cancer.
-
LASSBio-1829 hydrochloride
0 ImagesCat. No.: HY-118973CAS No.: 1807810-16-7LASSBio-1829 hydrochloride is an orally active IKK2 inhibitor with an IC50 of 3.8 μM against the human target (Sf21 cells). LASSBio-1829 hydrochloride blocks signal transduction of the inflammation-associated NF-κB activation pathway. LASSBio-1829 hydrochloride reduces leukocyte migration, TNF-α biosynthesis, ROS production and NO production. LASSBio-1829 hydrochloride exhibits anti-inflammatory activity in a carrageenan-induced subcutaneous air pouch mouse model. LASSBio-1829 hydrochloride alleviates licking behavior during the inflammatory phase of the mouse formalin test. LASSBio-1829 hydrochloride can be used in inflammation-related research.
